We are committed to delivering life-changing therapies for patients with rare and devasting metabolic diseases.
We believe every patient deserves a partner on their journey and we are interested in collaborating with companies that share our mission to meet the needs of these underserved patient communities. We aim to accelerate and expand our pipeline of innovative human enzymes through partnerships in our core areas of focus in rare disease.
We are open to new opportunities with both corporate and academic partners at all stages of development. If you are interested in partnering with Aeglea, please contact us at [email protected].
In March 2021, Aeglea entered into a license and supply agreement with Immedica Pharma AB for the commercialization of pegzilarginase in Europe and several Middle Eastern countries. Read more about the partnership.